CD40 activation of B-CLL cells is associated with augmented intracellular levels of CD79b and increased BCR expression in a subset of patients 1 yet, the intracellular expression of Ig, CD79a, and CD79b has been less carefully evaluated. Since different mechanistic explanations have been proposed for this phenomenon, including (i) somatic mutations of the B29 gene, 2 (ii) overexpression of a product of alternative splicing of CD79b, 3 or (iii) a defect in the transport of normally synthesized BCR components to the cell surface; 4 and surface analysis cannot discern between these possibilities, we performed a thorough analysis of surface and intracellular expression of all BCR components in B-CLL cells (Indraccolo S et al, in preparation). We found a heterogeneous pattern of expression of the BCR components in 22 B-CLL samples studied, ranging from those whose phenotype was similar to normal B cells (2/22) , to others which almost lacked intracellular IgM expression (3/22) . The relative majority of the B-CLL samples (17/22), however, presented with a sort of dichotomy in the surface and intracellular expression levels of the BCR molecules; intracellular staining was considerably stronger than membrane-associated reactivity (not shown). Interestingly, in about one-third of these samples (9/22), low-level intracellular reactivity was detected principally for CD79b.
We next investigated the possibility of modulating endogenous CD79b levels and analyzed the phenotypic changes in these cells in terms of BCR expression. Cells from seven B-CLL patients, representative of the different patterns of expression of BCR components described above, were activated in vitro by anti-CD40 þ IL-4 treatment which, as expected, resulted in a marked upregulation of CD54 expression in all samples, either in terms of percentage of CD54 þ cells or MFI values (Table 1 and Figure 1a ). These phenotypic changes were accompanied by a marked increase in the intracellular and surface levels of CD79b protein ( Figure 1a and Table 1 ), while changes in CD79b mRNA levels following CD40 activation were less apparent, as evaluated by RT-PCR analysis (Figure 1b ).
When surface IgM expression was analyzed, the B-CLL samples lacking intracellular CD79b (#6, #7, #11, and #14) showed a detectable increase in the percentage or the MFI of sIg, while B-CLL samples characterized by selective intracellular IgM deficiency (#3 and #5) had almost unchanged sIgM values (Table 1 and Figure 1a) . In a B-CLL sample (#15) characterized by the intracellular detection of all BCR components, albeit at reduced levels compared to normal B cells, a minimal variation in the percent of IgM þ cells was observed, in the presence of a marked increase in the MFI (Table 1) . Western blot analysis indicated that total IgM levels were slightly increased in one B-CLL sample (#7) and almost unchanged in the remaining four samples analyzed (data not shown), thus suggesting a predominant redistribution of a pre-existing IgM pool, rather then increased IgM synthesis.
To investigate whether these phenotypic changes were functional, we crosslinked the BCR on the surface of stimulated or nonstimulated B-CLL cells with an anti-IgM antibody and analyzed phosphorylation of Syk, a component of the signal transduction machinery associated to the BCR in B cells. Syk showed a basal level of phosphorylation that did not appreciably increase following anti-IgM treatment of B-CLL cells. In contrast, Daudi cells, which were included as a positive control, disclosed a marked increased in P-Syk upon BCR crosslinking (Figure 1c) . In patients lacking intracellular CD79b, CD40 stimulation was associated with only a slight increase in P-Syk compared to nonstimulated B-CLL cells: intriguingly, however, P-Syk levels were significantly increased following anti-IgM treatment of CD40-stimulated B-CLL cells, indicating that the BCR became functionally active. By contrast, no changes in the level of P-Syk following CD40 stimulation and anti-IgM treatment were measured in B-CLL cells from patient #5, whose phenotypic feature was lack of intracellular IgM (Figure 1c) . This is the first evidence, at the best of our knowledge, of marked effects of CD40 engagement on BCR expression in B-CLL cells. The most prominent observation was the increase in the intracellular levels of CD79b protein, which occurred in all samples analysed, but translated into phenotypic changes only in patients selectively lacking this component of the BCR. On the other hand, we did not measure a substantial increase in CD79b mRNA levels in the treated B-CLL samples, which may indicate that CD79b synthesis is regulated mainly at the post-transcriptional level in CD40/IL-4-activated B-CLL cells. Of note, the CD40 signature in B cells has recently been obtained, 5 and CD79b is not among the most upregulated genes at the mRNA level, thus corroborating our RT-PCR findings.
Relevant to the experiments discussed here, Payelle-Brogard et al 6 recently reported a significant increase in CD79b intracellular synthesis following treatment of B-CLL cells with CD40L þ IL-4; in their small cohort of patients (n ¼ 4) however, stimulation was not reported to induce marked upregulation of sIg levels. Since, according to our findings, CD40 stimulation may translate into increased BCR expression only in B-CLL cells selectively lacking CD79b, it is tempting to speculate that phenotypic differences in the clinical samples may explain these discrepancies between the two studies.
The BCR is a key component in B cells and both proliferative and apoptotic signals have been delivered through its engagement. Although circulating B-CLL cells are essentially nonproliferating, it has recently been observed that B-CLL cells within the pseudofollicles of lymph-nodes express both the proliferation antigen Ki67 and survivin, an inhibitor of apoptosis. 7 Intriguingly, survivin was found expressed in vitro following CD40 activation of B-CLL cells. 7 Our finding that BCR expression is increased by CD40 engagement and, more importantly, that the restored BCR was able to mediate phosphorylation events in B-CLL cells may suggest that B-CLL cells upon physiologic CD40 activation in the lymphoid microenvironment become responsive to proliferative signals delivered through the BCR. Thus, CD40-triggered upregulation of a functional BCR in a subset of B-CLL samples could underscore the transient acquisition of proliferative competence in a subset of B-CLL cells, which may be required to maintain the accumulating compartment. It would be interesting in future studies to investigate whether BCR expression is upmodulated in B-CLL cells within pseudofollicles.
In conclusion, our findings underline that reduced availability of CD79b protein may explain the phenotype of B-CLL cells in a subset of patients and describe previously unknown effects of CD40-mediated activation of these cells.
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